242 related articles for article (PubMed ID: 30319138)
1. Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma.
Xu W; Chen F; Fei X; Yang X; Lu X
Med Sci Monit; 2018 Oct; 24():7357-7365. PubMed ID: 30319138
[TBL] [Abstract][Full Text] [Related]
2. SMYD2 overexpression is associated with tumor cell proliferation and a worse outcome in human papillomavirus-unrelated nonmultiple head and neck carcinomas.
Ohtomo-Oda R; Komatsu S; Mori T; Sekine S; Hirajima S; Yoshimoto S; Kanai Y; Otsuji E; Ikeda E; Tsuda H
Hum Pathol; 2016 Mar; 49():145-55. PubMed ID: 26826421
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of G Protein-Coupled Receptor Kinase 6 (GRK6) Is Associated with Progression and Poor Prognosis of Papillary Thyroid Carcinoma.
Che X; Zhang G; Zhang X; Xue J
Med Sci Monit; 2018 May; 24():3540-3548. PubMed ID: 29805156
[TBL] [Abstract][Full Text] [Related]
4. USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma.
Jia M; Guo Y; Lu X
Cell Physiol Biochem; 2018; 45(5):2044-2053. PubMed ID: 29533940
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of SMYD2 contributes to malignant outcome in gastric cancer.
Komatsu S; Ichikawa D; Hirajima S; Nagata H; Nishimura Y; Kawaguchi T; Miyamae M; Okajima W; Ohashi T; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Imoto I; Inazawa J; Otsuji E
Br J Cancer; 2015 Jan; 112(2):357-64. PubMed ID: 25321194
[TBL] [Abstract][Full Text] [Related]
6. Expression of WD Repeat Domain 5 (WDR5) is Associated with Progression and Reduced Prognosis in Papillary Thyroid Carcinoma.
Xu W; Wang L; An Y; Ye J
Med Sci Monit; 2019 May; 25():3762-3770. PubMed ID: 31107859
[TBL] [Abstract][Full Text] [Related]
7. SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma.
Liu Y; Luo X; Deng J; Pan Y; Zhang L; Liang H
Tumour Biol; 2015 Apr; 36(4):2685-94. PubMed ID: 25472580
[TBL] [Abstract][Full Text] [Related]
8. Positive Expression of SMYD2 is Associated with Poor Prognosis in Patients with Primary Hepatocellular Carcinoma.
Zuo SR; Zuo XC; He Y; Fang WJ; Wang CJ; Zou H; Chen P; Huang LF; Huang LH; Xiang H; Liu SK
J Cancer; 2018; 9(2):321-330. PubMed ID: 29344279
[No Abstract] [Full Text] [Related]
9. Correlations of HOTAIR expression with pathological stage, CT characteristics and prognosis of patients with papillary thyroid carcinoma.
Chen X; Jin J; Zheng L; Sheng Y; Sun J
J BUON; 2021; 26(1):259-265. PubMed ID: 33721460
[TBL] [Abstract][Full Text] [Related]
10. Effect of miRNA-200b on the proliferation of liver cancer cells via targeting SMYD2/p53 signaling pathway.
Fang W; Song L; Li Z; Meng P; Zuo S; Liu S
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 47(10):1303-1314. PubMed ID: 36411681
[TBL] [Abstract][Full Text] [Related]
11. Tripartite Motif Containing 3 inhibits the aggressive behaviors of papillary thyroid carcinoma and indicates lower recurrence risk.
Song Y; Gao Z; Yan Z; Zheng C
Genes Genomics; 2022 Apr; 44(4):455-465. PubMed ID: 34860317
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of SMYD3 Is Predictive of Unfavorable Prognosis in Hepatocellular Carcinoma.
Fei X; Ma Y; Liu X; Meng Z
Tohoku J Exp Med; 2017 Nov; 243(3):219-226. PubMed ID: 29187705
[TBL] [Abstract][Full Text] [Related]
13. SMYD2 promotes tumorigenesis and metastasis of lung adenocarcinoma through RPS7.
Wu L; Kou F; Ji Z; Li B; Zhang B; Guo Y; Yang L
Cell Death Dis; 2021 May; 12(5):439. PubMed ID: 33935284
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma.
Komatsu S; Imoto I; Tsuda H; Kozaki KI; Muramatsu T; Shimada Y; Aiko S; Yoshizumi Y; Ichikawa D; Otsuji E; Inazawa J
Carcinogenesis; 2009 Jul; 30(7):1139-46. PubMed ID: 19423649
[TBL] [Abstract][Full Text] [Related]
15. EZH2 upregulation by ERα induces proliferation and migration of papillary thyroid carcinoma.
Xue L; Yan H; Chen Y; Zhang Q; Xie X; Ding X; Wang X; Qian Z; Xiao F; Song Z; Wu Y; Peng Y; Xu H
BMC Cancer; 2019 Nov; 19(1):1094. PubMed ID: 31718595
[TBL] [Abstract][Full Text] [Related]
16. Expression and clinical significance of STIP1 in papillary thyroid carcinoma.
Yuan MH; Zhou RS; She B; Xu HF; Wang JY; Wei LX
Tumour Biol; 2014 Mar; 35(3):2391-5. PubMed ID: 24163084
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of SET and MYND domain-containing protein 2 (
Zhang P; Ruan J; Weng W; Tang Y
Leuk Lymphoma; 2020 Feb; 61(2):437-444. PubMed ID: 31612757
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of SMYD3 was associated with increased STAT3 activation in gastric cancer.
Liu Y; Deng J; Luo X; Pan Y; Zhang L; Zhang R; Liang H
Med Oncol; 2015 Jan; 32(1):404. PubMed ID: 25471787
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of miR-127 Predicts Poor Prognosis and Contributes to the Progression of Papillary Thyroid Cancer by Targeting REPIN1.
Sun Y; Sun W; Hua H; Zhang J; Yu Q; Wang J; Liu X; Dong A
Horm Metab Res; 2021 Mar; 53(3):197-203. PubMed ID: 33339069
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of SMYD3 and matrix metalloproteinase-9 are associated with poor prognosis of patients with gastric cancer.
Liu Y; Liu H; Luo X; Deng J; Pan Y; Liang H
Tumour Biol; 2015 Jun; 36(6):4377-86. PubMed ID: 25627005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]